Immix Biopharma Australia Pty Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Los Angeles CA United States (2012)

Organization Overview

First Clinical Trial
2018
NCT03382340
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Immix Biopharma Australia Pty Ltd | Immix Biopharma, Inc. | Nexcella Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

imx-110 (2 trials)

tislelizumab (1 trial)

Drugs in Phase 1 Trials (1)

nxc-201 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3